EUVIMEDEUVIMED entdecken
Crossref

Dual Positivity for AMA / AMA ‐ M2 and Anti‐gp210/sp100 Shows Highest Diagnostic Value for Primary Biliary Cholangitis

Hong-Li Liu iD, Xing Liu, Yi-Fan Hu, Miao-Yang Chen, Sha-Sha Li, Xi-Xuan Wang, Yi-Jun Bao, Yu Zhang, Li Wang, Rui-Qi Li, Shu-Ling Chen, Qing-Fang Xiong und 4 weitere

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70614 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Hong-Li Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease and Liver Disease & Outpatient, Follow-Up Center, Nanjing Key Laboratory of Hepatology, The Second Hospital of Nanji…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary, Autoantibodies, Autoantigens, Nuclear Pore Complex Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Construction Project of Jiangsu Provincial Medical Innovation Center, Jiangsu Municipal Health Commission, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary biliary cholangitis (PBC)–related antibodies—including anti‐mitochondrial antibodies (AMA), AMA‐M2, anti‐gp210, and anti‐sp100—can occur in non‐PBC liver diseases. We evaluated single and combined antibody positivity, focusing on dual positivity, using liver biopsy as the reference standard.

Methods

This retrospective study included antibody‐positive patients who underwent liver biopsy. Patients were classified into three groups: only AMA(s) positive group, only anti‐gp210/sp100 positive group, and dual‐antibody positive group. Clinical and biochemical characteristics were compared to evaluate diagnostic performance and disease severity. Antibody‐positive patients who did not initially meet diagnostic criteria for PBC were followed to assess diagnostic conversion.

Results

Among 733 antibody‐positive patients, 80.22% (588/733) were diagnosed with PBC, while 19.78% (145/733) were non‐PBC. Diagnostic rates were 80.05% (313/391) in the only AMA(s) positive group, 53.85% (63/117) in the only anti‐gp210/sp100 positive group, and 94.22% (212/225) in the dual antibody positive group ( p < 0.05). Dual antibody positive patients showed the most severe cholestatic profile, with significantly higher alkaline phosphatase, gamma‐glutamyl transferase, total bile acid, and immunoglobulin M levels. The only anti‐gp210/sp100 positive group had the highest rate of gastrointestinal bleeding. Autoimmune hepatitis overlap was more common in the dual‐positive group than the only AMA(s) positive group ( p < 0.05). Among 145 non‐PBC patients followed for a median of 39.10 months, 2.07% (3/145) progressed to PBC, with a cumulative incidence of 7.40%.

Conclusions

Histopathology remains the definitive standard for diagnosing PBC. Dual positivity for AMA/AMA‐M2 and anti‐gp210/sp100 showed the highest diagnostic value in identifying PBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver Cirrhosis, BiliaryAutoantibodiesAutoantigensNuclear Pore Complex ProteinsMitochondriaHumansRetrospective StudiesFemaleMaleMiddle AgedBiopsyAgedAdultAntigens, Nuclear

Stichwörter der Autor:innen

AMA/AMA‐M2anti‐gp210anti‐sp100diagnostic valueprimary biliary cholangitis

Substanzen

AutoantibodiesAutoantigensNUP210 protein, humanSP100 protein, humanNuclear Pore Complex ProteinsAntigens, Nuclear

Autor:innen und Institutionen

  • Department of Infectious Disease and Liver Disease & Outpatient, Follow-Up Center, Nanjing Key Laboratory of Hepatology, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, Chi…
  • Department of Infectious Disease and Liver Disease & Outpatient, Follow-Up Center, Nanjing Key Laboratory of Hepatology, The Second Hospital of Nanjing, Teaching Hospital of Southeast University, Nanjing, China.
  • Department of Infectious Disease and Liver Disease & Outpatient, Follow-Up Center, Nanjing Key Laboratory of Hepatology, The Second Hospital of Nanjing, Clinical Teaching Hospital of Medical School, Nanjing University,…
  • Department of Pathology, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.

ORCID-Profile: Hong-Li Liu

Förderung

  • Construction Project of Jiangsu Provincial Medical Innovation Center
  • Jiangsu Municipal Health Commission
  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Liu, H. L., Liu, X., Hu, Y. F., Chen, M. Y., Li, S. S., Wang, X. X., Bao, Y. J., Zhang, Y., Wang, L., Li, R. Q., Chen, S. L., Xiong, Q. F., Zhong, Y. D., Liu, D. X., Zhang, K., & Yang, Y. F. (2026). Dual Positivity for AMA / AMA ‐ M2 and Anti‐gp210/sp100 Shows Highest Diagnostic Value for Primary Biliary Cholangitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70614

Vancouver

Liu HL, Liu X, Hu YF, Chen MY, Li SS, Wang XX, et al. Dual Positivity for AMA / AMA ‐ M2 and Anti‐gp210/sp100 Shows Highest Diagnostic Value for Primary Biliary Cholangitis. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70614

BibTeX
@article{Liu2026,
  author = {Liu, Hong-Li and Liu, Xing and Hu, Yi-Fan and Chen, Miao-Yang and Li, Sha-Sha and Wang, Xi-Xuan and Bao, Yi-Jun and Zhang, Yu and Wang, Li and Li, Rui-Qi and Chen, Shu-Ling and Xiong, Qing-Fang and Zhong, Yan-Dan and Liu, Du-Xian and Zhang, Kai and Yang, Yong-Feng},
  title = {Dual Positivity for AMA / AMA ‐ M2 and Anti‐gp210/sp100 Shows Highest Diagnostic Value for Primary Biliary Cholangitis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70614}
}
Kostenlos starten →